Demonstrates enhanced functionalization of cyclic peptides via on-resin techniques, suggesting improved therapeutic potential.
Cyclic peptides represent an important class of therapeutic molecules, however, often require late-stage functionalization to address suboptimal pharmacokinetic properties. Solid phase bifunctional cyclization strategies that enable both macrocyclization and diversification within a single scaffold remain limited. Herein, we report a general on-resin platform that exploits the 5-iodo-1,4-triazole as a bifunctional macrocyclic disulfide bridge mimetic, enabling modular late-stage modification of cyclic peptides. The methodology was demonstrated across a diverse panel of peptides spanning 6-12 residue macrocycles, incorporating varied amino acid side chains, N-terminal protecting groups, and peptide topologies. Formation of the 5-iodo-1,4-triazole was compatible with functionally diverse sequences under Fmoc-based solid-phase peptide synthesis conditions, highlighting the robustness of the cyclization strategy. Optimization of on-resin Suzuki-Miyaura cross-coupling significantly reduced reaction times while maintaining high conversions, enabling efficient aryl diversification of the triazole linkage. To expand structural scope, a complementary on-resin Sonogashira cross-coupling protocol was developed, allowing direct installation of alkyl linkers, functional handles, and biologically relevant motifs that are inaccessible through aryl-based cross-coupling alone. Together, these orthogonal palladium-catalyzed transformations establish a unified, operationally simple platform for the synthesis and late-stage diversification of cyclic peptidomimetics, providing rapid access to structurally diverse macrocyclic peptides relevant to chemical biology and medicinal chemistry.
No takes yet. Share an insight, caveat, or question.
Malone et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: